Back to Journals » Research and Reports in Urology » Volume 12

Focus on Silodosin: Pros and Cons of Uroselectivity

Authors Califano G, Collà Ruvolo C, Creta M, Capece M, La Rocca R, Celentano G, Napolitano L, Calace FP, Spena G, Trama F, Crocetto F, Mangiapia F, Longo N, Fusco F

Received 17 October 2020

Accepted for publication 17 December 2020

Published 23 December 2020 Volume 2020:12 Pages 669—672

DOI https://doi.org/10.2147/RRU.S287129

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Jan Colli


Gianluigi Califano,1 Claudia Collà Ruvolo,1 Massimiliano Creta,1 Marco Capece,1 Roberto La Rocca,1 Giuseppe Celentano,1 Luigi Napolitano,1 Francesco Paolo Calace,1 Gianluca Spena,1 Francesco Trama,1 Felice Crocetto,1 Francesco Mangiapia,1 Nicola Longo,1 Ferdinando Fusco2

1Department of Neurosciences, Reproductive Sciences and Odontostomatology – Federico II University of Naples, Naples, Italy; 2Department of Urology, Luigi Vanvitelli University of Naples, Naples, Italy

Correspondence: Massimiliano Creta
Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, via Sergio Pansini 5, Naples 80131, Italy
Tel/Fax +390817462611
Email max.creta@gmail.com

Abstract: Medical management of lower urinary tract symptoms related to benign prostatic obstruction engages healthcare professionals worldwide. Currently, alpha-1 adrenergic antagonists are strongly recommended as first-line therapy for patients with moderate to severe symptoms because of their safety, efficacy and good tolerability. These agents are highly heterogeneous in terms of pharmacological selectivity for the adrenergic receptor subtypes with silodosin being the agent characterized by the highest α1A1B affinity ratio. This property has been proposed to confer to silodosin advantages in terms of bladder outlet obstruction improvement and lower incidence of cardiovascular side effects at the cost of a higher incidence of ejaculatory dysfunction. These aspects should be carefully taken in consideration when personalizing medical therapy for lower urinary tract symptoms related to benign prostatic obstruction.

Keywords: alpha-1 adrenergic antagonists, benign prostate enlargement, lower urinary tract symptoms, bladder outlet obstruction

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]